1461087661-b36b2606-ec74-413b-a3be-9445e8a5beaa

1. An isolated antibody or antigen-binding fragment thereof that binds to a free C5a polypeptide, wherein the free C5a is a human polypeptide (hC5a) having the amino acid sequence depicted in SEQ ID NO:1, and wherein the antibody or antigen-binding fragment thereof binds to the free hC5a polypeptide in vitro with a KD that is less than 1.25\xd710\u22129 M in the presence of a molar excess of uncleaved, native human C5.
2. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the concentration of uncleaved, native human C5 is between 2-fold and 20-fold greater than the concentration of free hC5a.
3-4. (canceled)
5. An isolated antibody or antigen-binding fragment thereof that binds to a free C5a polypeptide, wherein the free C5a polypeptide is a human polypeptide (hC5a) having the amino acid sequence depicted in SEQ ID NO:1, wherein the antibody or antigen-binding fragment thereof binds to the human C5a polypeptide with a KD that is less than 1.25\xd710\u22129 M, wherein the antibody or antigen-binding fragment thereof binds to free hC5a polypeptide with an affinity that is at least 100-fold greater than its corresponding affinity for uncleaved human C5.
6. (canceled)
7. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds to free C5a from a non-human mammalian species.
8. An isolated antibody or antigen-binding fragment thereof that: (a) binds to a free human C5a polypeptide and (b) binds to a free C5a polypeptide from a non-human species, wherein the antibody or antigen-binding fragment thereof binds to the free hC5a polypeptide with a KD that is less than 1.25\xd710\u22129 M.
9. The isolated antibody or antigen-binding fragment thereof of claim 7, wherein the non-human mammalian species is a non-human primate.
10. The isolated antibody or antigen-binding fragment thereof of claim 9, wherein the non-human primate is a cynomolgus macaque, rhesus macaque, or baboon.
11. The isolated antibody or antigen-binding fragment thereof of claim 7, wherein the antibody or antigen-binding fragment thereof binds to free hC5a with an affinity no greater than 100-fold its corresponding affinity for free C5a from the non-human mammalian species.
12-14. (canceled)
15. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof comprises:
(a) a light chain polypeptide comprising:
(i) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:21; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:22; or
(ii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:38; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:22; and

(b) a heavy chain polypeptide comprising:
(i) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:29; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:30; or
(ii) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:46; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:47.
16-20. (canceled)
21. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the isolated antibody or antigen-binding fragment thereof comprises:
(a) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:37 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:27;
(b) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:36 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:33;
(c) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:19 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:27;
(d) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:17 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:25;
(e) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:42 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:27;
(f) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:40 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:33;
(g) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:17 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:33;
(h) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:19 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:45;
(i) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:17 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:44;
(j) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:17 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:49;
(k) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:37 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:45; or
(l) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:36 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:49.
22-41. (canceled)
42. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the isolated antibody or antigen-binding fragment thereof comprises:
(i) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:42 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:45;
(ii) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:40 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:49; or
(iii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:21; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:22; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:46; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:47.
43-47. (canceled)
48. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds to hC5a with a KD that is less than 8.0\xd710\u221211 M.
49. (canceled)
50. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody inhibits by at least 90% human C5a-dependent human neutrophil activation at a molar ratio of 1:1 (antigen-binding site: C5a).
51. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof inhibits the interaction between C5a and a C5a receptor.
52-57. (canceled)
58. The isolated antibody or antigen-binding fragment of claim 1, wherein the antibody or antigen-binding fragment is selected from the group consisting of a monoclonal antibody, a humanized antibody, a fully human antibody, a recombinant antibody, a bispecific antibody, a single chain antibody, a diabody, an intrabody, a chimerized or chimeric antibody, a deimmunized human antibody, an Fv fragment, an Fd fragment, an Fab fragment, an Fab\u2032 fragment, and an F(ab\u2032)2 fragment.
59-71. (canceled)
72. An antibody or antigen-binding fragment thereof that crossblocks the binding of the antibody or antigen-binding fragment thereof of claim 1.
73. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 1 and a pharmaceutically-acceptable carrier.
74. A nucleic acid encoding the antibody or antigen-binding fragment thereof of claim 1.
75-89. (canceled)
90. A method for treating a complement-associated disorder, the method comprising administering to a human in need thereof an antibody or antigen-binding fragment thereof of claim 1 in an amount sufficient to treat a complement-associated disorder afflicting the human.
91. (canceled)
92. The method of claim 90, wherein the complement-associated disorder is selected from the group consisting of atypical hemolytic uremic syndrome, age-related macular degeneration, severe burn, rheumatoid arthritis, sepsis, lupus nephritis, a complement-associated pulmonary disorder, and antiphospholipid syndrome.
93-100. (canceled)
101. An isolated antibody or antigen-binding fragment thereof that binds to mouse C5a, the antibody comprising:
(A)
(i) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:54; (ii) a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:55; and (iii) a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:56; (iv) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:62; (v) a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:63; and (vi) a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:64; or
(B)
a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:59; and
a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:66.
102-104. (canceled)
105. An isolated antibody, or antigen-binding fragment thereof, comprising;
(A)
a light chain polypeptide comprising:
(i) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:140; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:96; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:142;
(ii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:156; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:157; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:158;
(iii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:164; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:165; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:166;
(iv) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:172; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:173; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:174;
(v) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:84; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:85; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:86;
(vi) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:92; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:89; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:93;
(vii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:88; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:89; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:90;
(viii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:95; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:96; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:97;
(ix) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:99; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:100; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:101;
(x) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:84; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:85; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:103;
(xi) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:105; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:106; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:107;
(xii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:92; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:89; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:108;
(xiii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:110; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:111; or
(xiv) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:21; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:113; and
a heavy chain polypeptide comprising:
(i) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:144; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117;
(ii) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:67; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:30;
(iii) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:160; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:161; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:162;
(iv) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:168;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:169; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:170;
(v) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:176; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:177; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:178;
(vi) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:116; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117;
(vii) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:119;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:120; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:121;
(viii) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:123; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117;
(ix) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:124; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117;
(x) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:119; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:126; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:127;
(xi) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:129; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117;
(xii) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:131; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:132; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:133;
(xiii) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:46; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:47; or
(xiv) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:136; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:137; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:138;
(B)
a paired set of light chain CDR sequences and heavy chain CDR sequences as paired in Table 3 or Table 9; or
(C)
(i) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:140; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:96; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:142; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:144; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117;
(ii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:21; and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:22; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:67; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:30;
(iii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:156; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:157; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:158; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:160; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:161; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:162;
(iv) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:164; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:165; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:166; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:168; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:169; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:170;
(v) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:172; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:173; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:174; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:176; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:177; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:178;
(vi) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:88; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:89; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:90; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:119; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:120; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:121;
(vii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:105; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:106; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:107; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:124; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117;
(viii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:84; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:85; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:86; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:116; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117;
(ix) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:110; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:111; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:136; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:137; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:138;
(x) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:21; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:113; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:46; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:47;
(xi) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:99; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:100; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:101; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:119; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:126; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:127;
(xii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:95; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:96; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:97; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:144; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117;
(xiii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:140; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:96; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:142; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:123; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117;
(xiv) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:105; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:106; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:107; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:123; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117;
(xv) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:92; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:89; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:108; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:144; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117;
(xvi) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:92; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:89; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:93; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:123; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117;
(xvii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:92; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:89; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:93; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:144; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117;
(xviii) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:84; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:85; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:103; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:129; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117;
(xix) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:95; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:96; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:97; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:123; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117;
(xx) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:84; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:85; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:103; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:144; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117; or
(xxi) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:21; a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:113; a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:131; a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:132; and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:133.
106-119. (canceled)
120. An isolated antibody comprising two antigen-binding sites, wherein each antigen-binding site independently can bind to free human C5a (hC5a) or uncleaved human C5 (hC5), and wherein, in an aqueous solution comprising: (i) a plurality of said antibodies and (ii) a molar excess of hC5 as compared to the molar amount of the antigen-binding sites, at equilibrium and under physiological conditions:
(a) at least 95% of said plurality of antibodies bind no more than one hC5 molecule;
(b) at least 95% of said plurality of antibodies retain at least one antigen-binding site available to bind free hC5a; or
(c) the two antigen-binding sites of no more than 5% of said plurality of antibodies are fully occupied by hC5 molecules.
121-125. (canceled)
126. The isolated antibody of claim 120, wherein each antigen-binding site independently can bind to free hC5a with a subnanomolar affinity.
127. The isolated antibody of claim 120, wherein the isolated antibody comprises:
(A)
(i) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20; (ii) a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:21; and (iii) a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:22; (iv) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28; (v) a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:46; and (vi) a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:47; or
(B)
a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:42 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:45.
128-130. (canceled)
131. A method for treating a human afflicted with a C5a-associated complement disorder, the method comprising administering to the human: (i) at least 1 mg of the antibody of claim 120 per kg body weight of the human to thereby partially or completely bind and sequester nanogram levels of free C5a for at least 12 days or (ii) the antibody of claim 120 in an amount sufficient to (a) achieve molar Cmax values substantially lower than the molar physiologic concentration of uncleaved hC5 and (b) partially or completely bind and sequester pathophysiologic levels of free C5a.
132-140. (canceled)

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A credential caching system comprising one or more subsystems to:
receive a set of authentication credentials;
store the set of authentication credentials in a credential cache memory, wherein the credential cache memory is coupled with a management controller;
supply the set of authentication credentials for automatic authentication during a reset or reboot; and
in the event of a security breach, clear the set of authentication credentials from the credential cache memory so that the set of authentication credentials may no longer be used for a reset or reboot.
2. The system of claim 1, wherein the credential cache memory is volatile memory and loses the set of authentication credentials upon a loss of power.
3. The system of claim 1, wherein the security breach is physically removing power.
4. The system of claim 1, wherein the security breach is opening a chassis containing the management controller.
5. The system of claim 1, wherein the set of authentication credentials is received from a key management server via a local network.
6. The system of claim 1, wherein the management controller is a remote access controller including an on-board processor and memory.
7. The system of claim 1, wherein the set of authentication credentials are encrypted in the credential cache memory.
8. An information handling system (IHS) comprising:
a processor;
a management controller coupled with the processor; and
a credential caching system comprising one or more subsystems to:
receive a set of authentication credentials;
store the set of authentication credentials in a credential cache memory, wherein the credential cache memory is coupled with the management controller;
supply the set of authentication credentials for automatic authentication during a reset or reboot; and
in the event of a security breach, clear the set of authentication credentials from the credential cache memory so that the set of authentication credentials may no longer be used for a reset or reboot.
9. The IHS of claim 8, wherein the credential cache memory is volatile memory and loses the set of authentication credentials upon a loss of power.
10. The IHS of claim 8, wherein the security breach is physically removing power.
11. The IHS of claim 8, wherein the security breach is opening a chassis containing the management controller.
12. The IHS of claim 8, wherein the set of authentication credentials is received from a key management server via a local network.
13. The IHS of claim 8, wherein the management controller is a remote access controller including an on-board processor and memory.
14. The IHS of claim 8, wherein the set of authentication credentials are encrypted in the credential cache memory.
15. A method for credential caching comprising:
receiving a set of authentication credentials;
storing the set of authentication credentials in a credential cache memory, wherein the credential cache memory is coupled with a management controller;
supplying the set of authentication credentials for automatic authentication during a reset or reboot; and
in the event of a security breach, clearing the set of authentication credentials from the credential cache memory so that the set of authentication credentials may no longer be used for a reset or reboot.
16. The method of claim 15, wherein the credential cache memory is volatile memory and loses the set of authentication credentials upon a loss of power.
17. The method of claim 15, wherein the security breach is physically removing power.
18. The method of claim 15, wherein the security breach is opening a chassis containing the management controller.
19. The method of claim 15, wherein the set of authentication credentials is received from a key management server via a local network.
20. The method of claim 15, wherein the management controller is a remote access controller including an on-board processor and memory.

1461087652-7184123c-e72b-4503-9224-39740b9593cf

1. A phase change memory comprising:
a phase change material; and
a dielectric in contact with said phase change material, said dielectric including an impurity to improve the adherence of the dielectric to said phase change material.
2. A memory according to claim 1, wherein said impurity is selected in the group consisting of: Si, As, Sb, Ge, B, In, Ti, P, Mo, and W.
3. A memory according to claim 1, wherein said impurity is silicon at a concentration of between 1016 and 1023 atomscm3.
4. A memory according to claim 1, wherein said impurity is an ion implanted impurity.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A tomographic optical microscope system for reconstructing an image of an object, the system comprising:
a system optical axis and at least one of a slit or an edge for creating a light beam profile having a diffraction image,
an optics for directing the light beam profile to the object,
a moving means for implementing a scanning of the object with the light beam profile such that the diffraction image of the light beam profile illuminates the object for scanning, and the light beam profile moves by the moving means transversally to the system optical axis,
at least one of a prism or a mirror for rotating the light beam profile with respect to the object, and for changing between a plurality of scanning directions,
a first photodetector for measuring an intensity of light passing through or reflected by the object as a function of a displacement of the light beam profile in order to generate a projection of the object for each scanning direction, and
a computer configured to tomographically reconstruct the image of the object from a plurality of the projections.
2. The microscope system according to claim 1, wherein one part of the light beam profile is reflected by a light beam splitter to a second photodetector, wherein the second photodetector is of the same type as the first photodetector and allows to measure a change in the intensity of the light beam profile reaching the object.
3. The microscope system according to claim 1, wherein the light beam profile is the diffraction image of the slit and has an intensity distribution with a constant function in the longitudinal direction of the slit.
4. The microscope system according to claim 1, wherein the system optical axis and the at least one of a slit or an edge comprises an edge insertable into the path of a light beam coming from a light source, the system optical axis and the at least one of a slit or an edge generating the light beam profile of varying cross section and confined by an edge.
5. The microscope system according to claim 3, wherein the slit is provided with a phase shifting material splitting the diffraction image of the slit and filling up a part of the slit.
6. The microscope system according to claim 1, wherein the first photodetector is selected from the group consisting of a semi-conductor based PIN photodetector and a photoelectron multiplier.
7. The microscope system according to claim 1, further comprising a means for examining the diffraction image of the system optical axis and the at least one of a slit or an edge, wherein the means for examining the diffraction image is a screen or a camera.
8. A tomographic method for reconstructing an image of an object with a tomographic optical microscope, the method comprising:
generating a light beam profile with a system optical axis and at least one of a slit or an edge such that the light beam profile has a diffraction image;
illuminating the object with the diffraction image;
scanning the object with the light beam profile along a plurality of scanning directions transverse to the system optical axis,
moving the light beam profile transversally to the system optical axis to implement the scanning of the object with the light beam profile;
rotating the light beam profile with respect to the object and changing between the plurality of scanning directions with at least one of a prism or a mirror;
measuring an intensity of a light passing through or reflected by the object with a first photodetector, wherein the light intensity is measured as a function of the displacement of the light beam profile,
generating a plurality of projections of the object that respectively correspond to the plurality of scanning directions; and
tomographically reconstructing the image of the object from the plurality of projections generated from the plurality of scanning directions.
9. The method according to claim 8, wherein the intensity of the light beam profile reaching the object is measured by a second detector being of the same type as the first detector.
10. The method according to claim 8, wherein the light beam profile is created by a slit.
11. The method according to claim 8, wherein the light beam profile is created by an edge pushed into the path of a light beam coming from a light source.
12. The method according to claim 8, further comprising:
repeating the scanning, measuring, generating, and reconstructing steps for various planes of the object, and
generating a three dimensional reconstructed image of the object from the reconstructed image of each plane.
13. The method according to claim 8, further comprising modifying the spatial intensity distribution of the light beam profile by apodisation, wherein the light beam profile is split by the apodisation.
14. The method according to claim 8, wherein the scanning is made from at least 180 directions.
15. The method according to claim 8, wherein an angle between adjacent scanning directions is between 90\xb0 and 0.1.
16. A tomographic optical microscope system for reconstructing an image of an object, the system consisting of:
a cylindrical lens for creating a light beam profile,
an optics for directing the light beam profile to the object,
a moving motor for implementing a scanning of the object with the light beam profile,
a rotating element for rotating the light beam profile with respect to the object, and for changing the direction of scanning,
a first photodetector, being a light intensity measuring means for measuring the full light intensity of light passing through or reflected by the object, wherein the function of the measured light intensity in accordance with the position of the scanning light beam profile gives one projection of the image of the object for each scanning, and
a computer program for tomographically reconstructing the image of the object from the projections.
17. The method according to claim 14, wherein the scanning is made from 360 to 1800 directions.
18. The method according to claim 15, wherein an angle between adjacent scanning directions is between 1\xb0 and 0.1\xb0.